HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Ikena Oncology (NASDAQ:IKNA) and maintained a price target of $18.
August 07, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ikena Oncology's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $18.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $18 indicates the firm's continued confidence in the stock's potential, which could drive investor sentiment and potentially the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100